Why is Hamlet BioPharma AB ?
Unrated Stock - No Analysis Available
Quality key factors
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-190.11%
EBIT to Interest (avg)
-30.81
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
19.72
EV to EBIT
-12.76
EV to EBITDA
-15.74
EV to Capital Employed
27.61
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-216.29%
ROE (Latest)
-150.48%
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
Technical Movement
4What is working for the Company
NET PROFIT(HY)
Higher at SEK -27.59 MM
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
-7What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at SEK -43.32 MM
NET PROFIT(9M)
At SEK -45.08 MM has Grown at -24.58%
ROCE(HY)
Lowest at -109.76%
Here's what is working for Hamlet BioPharma AB
Net Profit
Higher at SEK -27.59 MM
than preceding 12 month period ended Dec 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (SEK MM)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Hamlet BioPharma AB
Operating Cash Flow
Lowest at SEK -43.32 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (SEK MM)






